G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 25.4 PLN Market Closed
Market Cap: 33.5m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genomed SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Cash from Operating Activities
zł2m
CAGR 3-Years
1%
CAGR 5-Years
79%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Cash from Operating Activities
zł46.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Cash from Operating Activities
-zł716.1k
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
4%
B
Bioton SA
WSE:BIO
Cash from Operating Activities
zł37.8m
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Cash from Operating Activities
-zł5.3m
CAGR 3-Years
-58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Cash from Operating Activities
zł6.3m
CAGR 3-Years
17%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Genomed SA
Glance View

Market Cap
33.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Fairly Valued
Intrinsic Value
Price
G

See Also

What is Genomed SA's Cash from Operating Activities?
Cash from Operating Activities
2m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Cash from Operating Activities amounts to 2m PLN.

What is Genomed SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
79%

The average annual Cash from Operating Activities growth rates for Genomed SA have been 1% over the past three years , 79% over the past five years .

Back to Top